These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
300 related items for PubMed ID: 23078651
1. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study). Summerfield NJ, Boswood A, O'Grady MR, Gordon SG, Dukes-McEwan J, Oyama MA, Smith S, Patteson M, French AT, Culshaw GJ, Braz-Ruivo L, Estrada A, O'Sullivan ML, Loureiro J, Willis R, Watson P. J Vet Intern Med; 2012; 26(6):1337-49. PubMed ID: 23078651 [Abstract] [Full Text] [Related]
2. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy. O'Grady MR, Minors SL, O'Sullivan ML, Horne R. J Vet Intern Med; 2008; 22(4):897-904. PubMed ID: 18537880 [Abstract] [Full Text] [Related]
3. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. Boswood A, Häggström J, Gordon SG, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Watson P. J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080 [Abstract] [Full Text] [Related]
4. Long-term Outcome of Irish Wolfhound Dogs with Preclinical Cardiomyopathy, Atrial Fibrillation, or Both Treated with Pimobendan, Benazepril Hydrochloride, or Methyldigoxin Monotherapy. Vollmar AC, Fox PR. J Vet Intern Med; 2016 Nov; 30(2):553-9. PubMed ID: 26936799 [Abstract] [Full Text] [Related]
5. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir AV, O'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R. J Vet Intern Med; 2008 Nov; 22(5):1124-35. PubMed ID: 18638016 [Abstract] [Full Text] [Related]
6. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study. Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Åblad B, Bussadori CM, Glaus T, Kovačević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir A, Lynne O'Sullivan M, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R. J Vet Intern Med; 2013 Nov; 27(6):1441-51. PubMed ID: 24010489 [Abstract] [Full Text] [Related]
7. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study. Boswood A, Gordon SG, Häggström J, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Schummer C, Watson P. J Vet Intern Med; 2018 Jan; 32(1):72-85. PubMed ID: 29214723 [Abstract] [Full Text] [Related]
8. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. Fuentes VL, Corcoran B, French A, Schober KE, Kleemann R, Justus C. J Vet Intern Med; 2002 Jan; 16(3):255-61. PubMed ID: 12041654 [Abstract] [Full Text] [Related]
9. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial. Wess G, Kresken JG, Wendt R, Gaugele J, Killich M, Keller L, Simak J, Holler P, Bauer A, Küchenhof H, Glaus T. J Vet Intern Med; 2020 Nov; 34(6):2232-2241. PubMed ID: 32945575 [Abstract] [Full Text] [Related]
10. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration. Lake-Bakaar GA, Singh MK, Kass PH, Griffiths LG. J Vet Cardiol; 2015 Jun; 17(2):120-8. PubMed ID: 26007710 [Abstract] [Full Text] [Related]
11. Pimobendan in heart failure therapy--a silver bullet? Gordon SG, Miller MW, Saunders AB. J Am Anim Hosp Assoc; 2006 Jun; 42(2):90-3. PubMed ID: 16527909 [Abstract] [Full Text] [Related]
12. Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study. Schober KE, Rush JE, Luis Fuentes V, Glaus T, Summerfield NJ, Wright K, Lehmkuhl L, Wess G, Sayer MP, Loureiro J, MacGregor J, Mohren N. J Vet Intern Med; 2021 Mar; 35(2):789-800. PubMed ID: 33543810 [Abstract] [Full Text] [Related]
13. Pimobendan and its use in treating canine congestive heart failure. Bowles D, Fry D. Compend Contin Educ Vet; 2011 Nov; 33(11):E1. PubMed ID: 22101450 [Abstract] [Full Text] [Related]
14. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure. Häggström J, Lord PF, Höglund K, Ljungvall I, Jöns O, Kvart C, Hansson K. J Vet Intern Med; 2013 Nov; 27(6):1452-62. PubMed ID: 24128373 [Abstract] [Full Text] [Related]
15. A review of the pharmacology and clinical uses of pimobendan. Boyle KL, Leech E. J Vet Emerg Crit Care (San Antonio); 2012 Aug; 22(4):398-408. PubMed ID: 22928748 [Abstract] [Full Text] [Related]
16. Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure. Reina-Doreste Y, Stern JA, Keene BW, Tou SP, Atkins CE, DeFrancesco TC, Ames MK, Hodge TE, Meurs KM. J Am Vet Med Assoc; 2014 Sep 01; 245(5):534-9. PubMed ID: 25148095 [Abstract] [Full Text] [Related]
17. Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure. Mizuno M, Yamano S, Chimura S, Hirakawa A, Takusagawa Y, Sawada T, Maetani S, Takahashi A, Mizuno T, Harada K, Shinoda A, Uchida S, Takeuchi J, Mizukoshi T, Endo M, Uechi M. J Vet Med Sci; 2017 Jan 20; 79(1):29-34. PubMed ID: 27644192 [Abstract] [Full Text] [Related]
18. Prospective clinical trial evaluating spironolactone in Doberman pinschers with congestive heart failure due to dilated cardiomyopathy. Laskary A, Fonfara S, Chambers H, O'Sullivan ML. J Vet Cardiol; 2022 Apr 20; 40():84-98. PubMed ID: 34315691 [Abstract] [Full Text] [Related]
19. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. Lombard CW, Jöns O, Bussadori CM. J Am Anim Hosp Assoc; 2006 Apr 20; 42(4):249-61. PubMed ID: 16822763 [Abstract] [Full Text] [Related]
20. Assessment of diastolic function by Doppler echocardiography in normal Doberman Pinschers and Doberman Pinschers with dilated cardiomyopathy. O'Sullivan ML, O'Grady MR, Minors SL. J Vet Intern Med; 2007 Apr 20; 21(1):81-91. PubMed ID: 17338154 [Abstract] [Full Text] [Related] Page: [Next] [New Search]